logo

Gw Pharmaceuticals Plc (GWPH)



Trade GWPH now with
  Date
  Headline
12/29/2017 7:03:39 AM GW Pharma Submits MAA In Europe For Epidiolex In Treatment Of Lennox-Gastaut Syndrome And Dravet Syndrome
12/28/2017 7:04:09 AM GW Pharma Announces Acceptance Of NDA Filing For Epidiolex In Treatment Of Lennox-Gastaut Syndrome And Dravet Syndrome
12/13/2017 7:02:16 AM GW Pharma Reacquires Full Rights To Develop And Commercialize Sativex® In U.S.
12/6/2017 9:50:37 PM GW Pharmaceuticals Announces Pricing Of Public Offering Of ADSs Raising Gross Proceeds Of $276 Mln
12/4/2017 7:08:05 AM GW Pharma FY Revenue £8.2 Mln Or $11.0 Mln Vs £10.3 Mln Last Year
12/1/2017 2:51:57 AM In The Spotlight: Zogenix
10/30/2017 7:10:49 AM GW Pharmaceuticals Completes Rolling NDA Submission To FDA For Epidiolex
5/15/2017 7:09:18 AM GW Pharma Appoints Volker Knappertz As Chief Medical Officer; Ben Whalley To Join As Head Of Discovery Research
4/13/2017 7:09:10 AM GW Pharma And Its U.S. Subsidiary Greenwich Biosciences To Present Data On Epidiolex At 2017 AAN Annual Meeting
3/29/2017 7:05:31 AM GW Pharma Says Epidiolex Receives Orphan Drug Designation From The European Medicines Agency For Lennox-Gastaut Syndrome
3/7/2017 5:01:53 AM GW Pharma Names Scott Giacobello As CFO And Adam George As Managing Director - UK
2/7/2017 7:04:57 AM GW Pharma Q1 Revenue £2.1 Mln Or $2.5 Mln Vs £3.7 Mln Last Year
12/5/2016 7:11:16 AM GW Pharma 12-month Revenue £10.3 Mln Vs. £28.5 Mln Prior Year
12/1/2016 6:15:55 AM GW Pharma Announces Epidiolex Data Presentations And Educational Programs